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Abstract
Cervical cancer is primarily caused by human papillomavirus (HPV) and is the second
 most common cause of cancer-related mortality among women. Female college students
 may be at risk for contracting HPV based on their sexual behavior. Following the release
 of the HPV vaccine, Gardasil®, this cross-sectional study was developed to (1) determine
 awareness of HPV and Gardasil®, (2) assess attitudes, behaviors, and beliefs about the
 HPV vaccine, and (3) identify information sources that female college students are
 accessing. Female college students voluntarily completed a self-administered
 questionnaire. Statistical analyses included descriptive statistics, Pearson’s correlations
 and paired sample t-tests. Sexually active respondents would recommend the HPV
 vaccine to others and disagreed that vaccination would encourage risky sexual behavior.
 Correlations were identified on how self-reported knowledge influenced attitudes,
 behaviors, and beliefs regarding the HPV vaccine. These findings should assist in
 developing integrated public health education efforts for HPV vaccination that are
 targeted towards this at-risk population.
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Cervical cancer is a global public health issue that is second to breast cancer in overall
 cancer-related mortality among women. Cervical cancer presents a distinctive public
 health challenge since it is caused by a sexually transmitted virus; is gender specific; and
 primary and secondary public health prevention efforts target an expansive age range of
 women. 1 According to the American Cancer Society, in the United States (U.S.),
 approximately 9,710 women were diagnosed with cervical cancer, and 3,700 died from
 this disease in 2006. 2 On a global level, approximately 500,000 cases of cervical cancer
 are diagnosed on an annual basis which accounts for approximately 250,000 deaths
 among women. 3-6
The majority of cervical cancer is caused by a persistent infection with the human
 papillomavirus (HPV). 7 The Papanicolaou (Pap) cytology test has proven to be an
 effective screening tool in identifying the precursor lesion associated with HPV infection. 8
 HPV is a DNA virus with more than 100 different types having been identified;
 approximately 30 types are sexually transmitted. Low risk HPV types, HPV-6 and HPV-
11, are responsible for 90% of genital warts cases. High risk HPV types, HPV-16 and
 HPV-18, account for approximately 70% of cervical cancer cases. 9 HPV is one of the
 most common sexually transmitted infections in the world and studies suggest that
 approximately 90% of HPV infections resolve themselves within two years. It is the
 percentage of HPV infections that do not resolve themselves that have the potential to
 contribute to cervical cancer. 10,11 The prevalence of HPV has been found to be highest
 among young persons within the first few years after sexual activity is initiated. The
 prevalence of HPV infection was found to be highest among females aged 20-24 years.
 12,13 Each year, approximately 6.2 to 7.5 million Americans become infected with genital
 HPV. The Centers for Disease Control and Prevention (CDC) reported that, unless
 vaccinated, approximately 80% of sexually active women will acquire HPV by the age of
 50. 14
In June 2006, the Food and Drug Administration (FDA) approved the first prophylactic
 human papillomavirus vaccine, Gardasil ® , that has been shown to be effective against
 HPV types 6 and 11 which contribute to genital warts, and HPV types 16 and 18 which
 contribute to cervical cancer. Efficacy rates of the vaccine for clinical outcomes have
 approached 100% in preventing infection and disease in clinical trials of women aged 16
 to 24. 15 The CDC’s Advisory Committee on Immunization Practices currently
 recommends universal administration of three interval doses of the HPV vaccine,
 Gardasil ® , in girls 11 or 12 years of age. The recommendation also allows for females
 aged nine to 26 years to be vaccinated at the discretion of their physician. 16 Predictive
 public health strategies, such as administering the prophylactic HPV vaccine to all 12-
year-old girls in the U.S., estimate that more than 1,300 cervical cancer deaths among this
 susceptible population could be prevented. In addition, this public health approach could
 also prove to be cost effective if Pap tests were conducted at a later age and less
 frequently. Furthermore, a computer-based model estimated that HPV vaccination at age
 12 and Pap tests every three years starting at age 25 could potentially reduce a woman’s
 lifetime risk of cervical cancer by 94%. 17,18
Purpose
Early age of first sexual intercourse is associated with greater susceptibility to HPV
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 infection, possibly due to the immature status of the cervix. 19 In the U.S., sexual activity
 begins in ninth grade for 29.3% of girls, and 62.4% of twelfth grade girls report prior
 sexual activity. 20 Early sexual behavior warrants the importance of a prophylactic HPV
 vaccine for younger females, prior to becoming sexually active, in order to provide the
 most public health benefit. Furthermore, factors that have been associated with an
 increased risk of acquiring HPV include age, condom use, increasing cumulative number
 of sexual partners, sex with a new partner, knowing a partner less than a year, and
 marital status. 12,13,21,22
HPV has been detected in 99.7% of cervical cancer cases. 7 Dunne et al. found the
 overall prevalence of HPV to be 26.8% in U.S. females aged 14 to 59 years and 24.5%
 among females aged 14 to 19, and HPV prevalence was 44.8% for females 20 to 24
 years of age and 27.4% for females aged 25 to 29 years, and then decreased at older
 ages, possibly due to acquired immunity. 13 Moreover, several studies have shown that
 sexually active female college students in the 20-24 age group are often unaware of HPV
 and become aware of HPV only after being diagnosed with the HPV infection by a
 healthcare provider. 23,24 Thus, college age women may be at high risk for contracting
 HPV.
Kahn et al. explored the following variables in young women prior to the introduction of
 Gardasil ® : knowledge about HPV and the HPV vaccine; personal beliefs about HPV
 vaccination; belief that others would approve of HPV vaccination; number of sexual
 partners; and perceived support of healthcare provider, partner, and parents. They found
 that all factors were significantly associated with the intention to receive the HPV vaccine.
 25 Boehner et al. examined the acceptability of an HPV vaccine among college students
 several years before the HPV vaccine became available to the public and found that 74%
 of female college students would accept such a vaccine. 26 The purpose of our
 exploratory analysis is to expand upon this previous research by investigating, following
 the release of Gardasil ® , (1) what information sources female college students are
 accessing about the HPV vaccine; (2) how this knowledge has influenced attitudes,
 behaviors, and beliefs regarding the HPV vaccine among this population with respect to
 recommending the HPV vaccine to others, and whether or not receiving the HPV vaccine
 would encourage risky sexual behavior; and (3) correlations between social behavior
 (e.g., sexual practices, relationship status) and one’s concern about HPV infection and
 recommending the HPV vaccine to others. This information, collectively, may offer
 different views on a pertinent health issue that health educators may want to consider as
 they develop integrated public health education and immunization initiatives aimed at
 reducing the burden of HPV infection among female college students.
Methods
A cross-sectional study design was utilized for this exploratory analysis, in order to
 administer a self-report questionnaire to a relevant sample of 361 female college students
 from a large, public, state-supported Northeastern university in 2007. The university’s
 Institutional Review Board approved the study. Questionnaires were administered over a
 period of four weeks at different times and at several locations (e.g., University Health
 Services, Alpha Phi sorority, health class, aerobics class, and a choral rehearsal) on the
 university’s campus from the end of February through March 2007. Questionnaires were
 also distributed on campus to female college students enrolled at the university who were
 entering or departing scheduled classes and events. The anonymous surveys took an
 average of seven minutes to complete and were immediately collected from the
 participants upon completion. University Health Services administered surveys to female
 students as they waited for their appointments. Completed surveys were returned to the
 reception desk and were collected in a locked collection box.
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All questionnaires had a cover letter attached that explained the purpose of the study and
 emphasized the anonymity and confidentiality of the results. Students were told to keep
 this letter for their records. There were no incentives for participating in this study.
 Additional open ended comments from the participants were recorded at the end of the
 survey.
The 23-item questionnaire was designed to determine demographic information, level, and
 source of self-reported knowledge about HPV and the HPV vaccine and attitudes,
 behaviors, and beliefs about the HPV vaccine. Revisions were made during the pilot
 testing phase of the questionnaire. Ambiguities associated with the survey content were
 not identified during test trials that were conducted prior to official questionnaire
 administration.
Respondents were asked if they knew what HPV was and if they had heard of the HPV
 vaccine, Gardasil ® , prior to this survey (“Yes”/”No”/”Not sure” to both). In order to
 determine sources of information of the vaccine, respondents were asked to choose from
 the following sources: “Tell Someone” commercial, “One Less” commercial, talk show,
 news show, magazine advertisements, magazine articles, radio, newspaper articles,
 medical journals, Merck Pharmaceutical, Inc. web site, thehpvtest.com web site, general
 practitioner, nurse, other health professional, University Health Services, family, friends,
 and other. Respondents were instructed to circle all that applied to them.
Respondents were then asked if they would get the HPV vaccine if it were offered for free.
 Those who responded “No” or “Not sure” were asked a follow-up question to determine
 the reason for their response. There was also a question to determine what behavior
 changes have resulted from knowing about the HPV vaccine. Examples included: getting
 vaccinated against HPV; speaking with a healthcare professional about the HPV vaccine;
 sharing knowledge with family or friends; and engaging in further information gathering
 about the HPV vaccine and the link between cervical cancer and HPV.
Finally, information regarding the respondent’s attitude about the idea that HPV
 vaccination may lead to risky sexual behavior, a current controversial topic, was
 collected. Respondents were asked a series of questions to determine the degree to
 which they agree with statements about the HPV vaccine, such as should females
 between the ages of nine and 26 years of age get the HPV vaccine, and whether or not
 they were personally concerned about acquiring HPV. The questions were analyzed on a
 three-point scale, “Agree”/”Disagree”/”Not sure.”
All data were analyzed using the Statistical Package for Social Sciences (SPSS), Version
 15.0 for Windows. Descriptive analyses were done for each of the following participant
 responses: specific college the participant was enrolled in at the university; age (age
 groups analyzed: 17-18, 19-21, 21-24, ≥25 years); race; if have had sexual intercourse;
 age at which first had sexual intercourse; number of sexual partners (the number of
 sexual partners analyzed: 0, 1, 2, 3-5, ≥6); condom use; relationship status; overall health
 status; if receive regular Pap screening tests; knowledge of HPV; heard of Gardasil ®
 before survey; knowledge of the HPV vaccine; would get the HPV vaccine if it were
 offered for free; reasons for not getting the HPV vaccine if it were offered for free;
 behavior change(s) as a result of knowledge of the HPV vaccine; likelihood of
 recommending the HPV vaccine to others; agreement that females between the ages
 nine and 26 should get the HPV vaccine; belief that the HPV vaccine may encourage
 risky sexual behavior; and concern about possibly acquiring HPV.
Cross-tabulation analyses were done for the questions of interest and all demographic
 variables, as well as self-reported knowledge of HPV and the HPV vaccine. These
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 questions included: would get the HPV vaccine if it were offered for free; likelihood of
 recommending the HPV vaccine to others; agreement that females between the ages
 nine and 26 should get the HPV vaccine; agreement that HPV vaccination against a
 sexually transmitted infection may encourage risky sexual behavior; and concern about
 possibly acquiring HPV. Pearson’s chi-square tests and two-tailed t-tests were done to
 assess relationships between two variables. For statistical tests, P-values less than 0.05
 were considered to be statistically significant.
Results
The demographic and behavioral characteristics of female undergraduate respondents are
 shown in Table 1. Two hundred ninety-three of 361 surveys (81% response rate) were
 completed and returned by female college students enrolled at a large Northeastern State
 University. Female students, aged 18 to 34 years, voluntarily participated in the
 anonymous study. The mean age of the respondents was 20.4 years (standard deviation
 [SD] =0.125), and 93.5% of respondents were Caucasian. Based on a comparison to
 information compiled by the university’s Office of Institutional Research, the population
 demographics of our relevant sample are generalizable to the university’s undergraduate
 female population due to the relative similarities of the sample characteristics for gender
 and ethnicity to that of the university population. Non-traditional female students and
 female graduate students were underrepresented.
Figure 1




The majority responded that they had previously had sex (90.4%), and t-test results found
 the average age of women who responded “Yes” to previously having sex to be 20.5 and
 “No” to be 19.9 (P<0.014). T-test results showed that the majority of respondents did get
 regular Pap tests (78.8%), and the mean age of those women who did get regular Pap
 tests (20.6) was statistically significant (P<0.001) from those who did not (19.5). Also, the
 mean number of sexual partners among women who got regular Pap tests (4.6) was
 statistically significant (P<0.001) from those women who did not get regular Pap tests
 (2.4).
The majority of respondents both knew what HPV was (85%) and had heard of the HPV
 vaccine, Gardasil ® (85%), prior to completing this survey. The mean age of those who
 had heard of Gardasil ® (20.4) was statistically different (P<0.022) from those who were
 not sure (18.7). The majority of respondents who knew what HPV was had also heard of
 Gardasil ® (92%), but there was some inconsistency. For instance, of the participants
 who did not know what HPV was, 28.6% had heard of Gardasil ® .
The most common sources of information about the HPV vaccine among respondents
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 were the “Tell Someone” television commercial (64.9%) and the “One Less” television
 commercial (64.5%), both of which were developed by Merck Pharmaceuticals, Inc.
 Friends (41.8%) and family (31.9%) were the next most common sources of information
 regarding the HPV vaccine.
The majority of respondents would get the vaccine if it were offered for free (75.3%), and
 reasons for not getting the vaccine included “Need more information” (63.5%) and “Safety
 concerns” (39.4%). “Speaking to physician” (45.5%) and “Sharing your knowledge with
 others” (41.6%) were the most common behavior changes noted by respondents as a
 result of knowing about the HPV vaccine. There was a population of participants (16.2%)
 who answered that they had begun the HPV vaccination series. The mean age for those
 “early adopters” was 19.7 years. There was a statistically significant correlation (P<0.001)
 between those who had received the HPV vaccine and those who agreed that females
 between the ages of nine and 26 should get the HPV vaccine and were likely to
 recommend the vaccine to others.
We found several statistically significant associations between demographic variables and
 attitudes and behaviors with respect to the HPV vaccine. More than half of the
 respondents (52.9%) marked that “Yes,” they were concerned about possibly acquiring
 HPV. With cross-tabulation analysis, we found statistically significant associations
 between concern of acquiring HPV with each of the following variables: number of sexual
 partners (P<0.029); knowledge of HPV (P<0.002); if ever had sex (P<0.001); and current
 relationship status (P<0.001).
The majority of respondents (69.1%) were likely to recommend that others be vaccinated
 against HPV. The mean age for those respondents who were likely to recommend the
 HPV vaccine (20.4) was statistically different (P<0.025) from those who were not likely to
 recommend the HPV vaccine (19.6). Statistically significant associations were also found
 between the likelihood of recommending the HPV vaccine and the following variables:
 knowledge of HPV (P<0.001); knowledge of the HPV vaccine (P<0.001); if ever had sex
 (P<0.029); and if get regular Pap tests (P<0.002).
A high percentage of respondents (82.8%) agreed that females between the ages of nine
 and 26 should be vaccinated. Statistically significant associations with this statement
 were with knowledge of HPV (P<0.006) and current relationship status (P<0.022).
Finally, we addressed the controversial idea that vaccination against a sexually
 transmitted infection, specifically HPV, may encourage risky sexual behavior. The
 majority of respondents (65.3%) disagreed with this idea. The mean age of respondents
 who disagreed (20.6) was statistically different (P<0.03) from those who agreed (19.9).
 The most statistically significant correlations were found with this question and the
 following variables: knowledge of HPV (P<0.001); knowledge of the HPV vaccine
 (P<0.001); if ever had sex (P<0.001); number of sexual partners (P<0.021); age (P<0.04);
 and if get regular Pap tests (P<0.001) (Table 2).
Figure 2
TABLE 2. Characteristics of female undergraduate respondents and their belief that HPV




The public health benefits of HPV vaccination would be expected to significantly reduce
 HPV-related morbidity, treatment, and overall U.S. economic burden, which is estimated
 at more than $5 billion annually. 27 In addition, the HPV vaccine also has the potential to
 prevent cervical cancer cases that are currently undetected due to a lack of Pap test
 screening. 9 Although this population of female college students surveyed had heard of
 HPV and the HPV vaccine, the lack of knowledge was the predominant reason
 respondents would not get the HPV vaccine even if it were offered for free. In order to
 dispel a false sense of security among this at-risk population, our findings warrant
 integrated public health efforts among health educators on college campuses and in the
 private sector, among parents and community health professionals, to name a few
 resources, with respect to HPV infection and cervical cancer control via health behavior
 education. These coordinated public health education strategies should involve primary
 (e.g., HPV vaccination) and secondary (e.g., screening and early detection) prevention
 methods to significantly reduce the burden of these preventable illnesses among this
 vulnerable female population.
Previous studies have shown that college students have very little knowledge about HPV.
Internet Scientific Publications
https://ispub.com/IJH/9/2/9245[1/5/2015 9:06:32 AM]
 28-30 In contrast, our results suggest that the majority (85%) of female college students in
 our study do know what HPV is and have previously heard of the HPV vaccine, Gardasil
 ® . Interestingly, knowledge of HPV did not correlate directly to knowledge of the HPV
 vaccine. Conversely, 28.6% of women who did not know what HPV was, had heard of
 Gardasil ® . The “Tell Someone” and “One Less” television commercials developed by
 Merck Pharmaceuticals, Inc., were the most common sources of information about the
 HPV vaccine. Continued use of the media will be important to incorporate into future
 public health education and awareness efforts. While informing the viewer, the
 commercials also stress the importance of sharing knowledge with others. Family and
 friends were the next most common source of information about the HPV vaccine, and
 sharing knowledge with others was a behavior change noted by the respondents.
Our study results indicate strong correlations of self-reported knowledge about HPV and
 the HPV vaccine with the following themes:
Decision to get the HPV vaccine if it were offered for free. Although the majority (75.3%) of
 women were likely to receive the HPV vaccine if it were offered for free, the remainder of
 women responded “No” or “Not sure.” The most common reason for this was “Need more
 information.” The respondents expressed that they do not feel they have enough
 information to decide to get the HPV vaccine, even if it were offered for free. The women
 also expressed concerns about safety of the HPV vaccine, which is understandable as
 Gardasil ® is a new vaccine. Only 7% responded that they “Do not think the HPV vaccine
 is important.”
Likelihood of recommending the HPV vaccine to others and the belief that HPV
 vaccination will promote risky sexual behavior. Awareness of the HPV vaccine was
 another behavior that correlated significantly with the likelihood of recommending the
 vaccine to others and agreement that vaccination may encourage risky sexual behavior.
 Of those women who have heard of the HPV vaccine, 73.3% were likely to agree that
 others get the HPV vaccine. Of those women who had never heard of the HPV vaccine,
 41.5% were likely to recommend it and 43.9% were not sure if they would recommend the
 HPV vaccine. In general, awareness of the HPV vaccine correlated with women being
 more likely to recommend the HPV vaccine and with disagreement that HPV vaccination
 may encourage risky sexual behavior. Interestingly, all of the women who were not sure
 what the HPV vaccine was were likely to recommend it and also agreed that HPV
 vaccination may encourage risky sexual behavior. This information suggests that these
 women may not view risky sexual behavior with a negative connotation since they are
 likely to recommend a vaccine that they think encourages risky sexual behavior.
 Furthermore, the age of the respondents significantly correlated with agreement that HPV
 vaccination may encourage risky sexual behavior with older respondents disagreeing with
 this belief. These findings highlight the need for health behavior education regarding risky
 sexual activity and how to prevent HPV infection.
Agreement that females between the ages of nine and 26 should get the HPV vaccine.
 Interestingly, 82.8% of respondents agreed that females between the ages of nine and 26
 should be vaccinated, as compared to “likely” recommending that others receive the HPV
 vaccine. This may very well be due to women not feeling informed enough to responsibly
 recommend that others receive the vaccine. However, when asked whether to agree or
 disagree, women felt more comfortable agreeing that females between the ages nine and
 26 should be vaccinated.
Relationship status. Current relationship status of the respondents was a characteristic
 that provided statistically significant correlations with concern about possibly acquiring
 HPV and agreement that females between the ages nine and 26 should receive the HPV
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 vaccine. Of those women who were single or dating, the majority (56.1% and 58.8%,
 respectively) were concerned about acquiring HPV. Of those in monogamous
 relationships, 52.7% were concerned about acquiring HPV. Of those respondents who
 were married or living with a partner, more than half (54.5%) did not know or were not
 concerned about acquiring HPV. While women who are married or in a monogamous
 relationship may be at lesser risk for acquiring HPV, it is still a possibility. Therefore, this
 data emphasizes the importance of increased health educational awareness efforts, as
 women may be in high risk situations for acquiring HPV but not realize it. A majority of
 women, regardless of relationship status, agreed that females between the ages of nine
 and 26 should get the vaccine.
Sexual behavior and concern about possibly acquiring HPV. Of those women who
 previously had sexual intercourse, only slightly more than half (56.5%) were concerned
 about acquiring HPV. This low percentage leads us to believe that women may know
 what HPV is, but they are not aware of the infectivity and prevalence of HPV, especially
 among women of these vulnerable ages. Of those women who previously had sexual
 intercourse, 70.2% were likely to recommend that others receive the HPV vaccine, and
 68.3% disagreed that HPV vaccination may encourage risky sexual behavior. Of those
 participants who had not had previous sexual intercourse, 60.7% were also likely to
 recommend that others receive the HPV vaccine, and 32.1% agreed that HPV
 vaccination may encourage risky sexual behavior. The data illustrates that sexual
 experience does significantly influence attitudes and behaviors toward the HPV vaccine.
Number of sexual partners. The number of sexual partners was another characteristic that
 provided statistically significant correlations. For example, with an increasing number of
 sexual partners from zero to more than six, there was an increase in the percentage of
 respondents who were concerned about acquiring HPV. A previous study found that HPV
 seropositivity increased with the number of sexual partners, from 10% with one partner, to
 25% with two or three partners, and up to 53% with more than six partners. 31 Another
 study reported that each additional sexual partner added approximately 10% to the risk of
 acquiring HPV infection. 32 However, in our study, of those women who have had more
 than six sexual partners, 20% were not concerned about acquiring HPV. This is an
 alarming statistic that warrants the implementation of further public health HPV
 educational programs. It is possible that these women may feel comfortable with high-risk
 sexual activity if they believe they are protected from HPV infection by vaccination, hence
 a false sense of security. 30 In addition, there is a concern that an effective HPV vaccine
 would cause sexually active women to significantly reduce their adherence to obtaining
 Pap screening tests, thus leading to a potential increase in cervical cancer cases. 33
 These findings, again, point to the need for vaccine availability to be accompanied by
 proper ancillary awareness education.
Risky behaviors. Furthermore, the age at which one first had sexual intercourse, condom
 use, description of health status, and race did not provide statistically significant
 correlations. However, the frequency distributions highlight risky behaviors among this
 vulnerable population. For example, 18.3% of the respondents “Hardly ever” or “Never”
 used condoms with their male partners. Condom use has been associated with
 decreased risk of acquiring HPV among newly sexually active women. 21 The practice of
 not using condoms potentially puts these respondents at a higher risk for acquiring HPV
 infection.
Limitations. Although the findings from this exploratory analysis provide valuable insight
 into female college student attitudes, behaviors, and beliefs about HPV and the HPV
 vaccine, several limitations to this study should be noted. The sampling bias associated
 with a non-probability sampling technique is similar to other HPV studies in college
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 students and limits the generalizability of the findings from this study to female college
 students attending other universities. Yet, the sampling of female students in various
 classes and events provide enhanced representation. The sample characteristics were
 similar to the demographics of the university population and support the generalizability of
 findings for the sampled university. However, the findings cannot be applied to all female
 college students and may not be reflective of all young women. Future studies should use
 random samples from several universities to maximize the generalizability of the findings.
 Missing data occurred randomly across all surveys. In addition, the results were limited by
 the cross-sectional study design and compliance to the authenticity of self-reported
 information, such as HPV and HPV vaccine awareness. Despite these limitations, our
 findings have been appropriately qualified, and we propose that they provide valuable
 insight regarding selected correlates associated with sexual behavior and HPV
 vaccination. In addition, our findings warrant an educational intervention by health
 educators who may find this information useful when attempting to develop integrated
 public health education efforts that are targeted towards this at-risk population.
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